M29 Fvc decline over 1 year predicts mortality but not subsequent fvc decline in patients with ipf

Introduction: In the INPULSIS trials, nintedanib reduced disease progression by reducing FVC decline vs placebo in patients with IPF. Patients who completed an INPULSIS trial could receive open-label nintedanib in the extension trial INPULSIS-ON. Aim: Assess the impact of FVC decline in INPULSIS on FVC decline and mortality in INPULSIS-ON. Methods: Descriptive analysis of the proportions of nintedanib-treated patients who had FVC decline Results: 430 patients received nintedanib in both INPULSIS and INPULSIS-ON. Of these, 89.1% had FVC decline Conclusion: Independent of FVC decline in the first year, most patients had FVC decline